1. France Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
Amoeba SA

Amoeba SA

0.30
EUR
+0.00
(-0.67%)
46.35MMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.08
0.06
0.03
0.02
0.03
0.02
0.02
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.14
-0.26
-0.9
-1
-1.04
-1.2
-0.92
-0.5
-0.44
-0.24
-0.29
-0.13
-0.14
- -
Free Cash Flow per Basic Share
-0.01
-0.55
-1.42
-1.57
-1.01
-0.92
-0.45
-0.2
-0.25
-0.14
-0.26
-0.1
-0.12
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.12
0.74
1.98
3.11
2.09
0.9
0.34
0.12
0.01
0.18
-0.08
-0.21
-0.08
-0.21
Tangible Book Value per Share
-0.24
0.16
1.42
2.6
1.55
0.32
0.14
-0.03
-0.11
0.12
-0.08
-0.21
-0.08
-0.21
Basic Weighted Avg Shares
4
4
4
6
6
6
8
16
18
34
49
50
59
48
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-161.58
-414.82
-2,829.38
-4,567.86
-3,684.35
-4,456.77
-4,495.13
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
1
1
2
1
1
1
1
1
1
- -
Net Income, GAAP
-1
-1
-4
-6
-6
-7
-7
-8
-8
-8
-14
-7
-8
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-172.43
-438.07
-2,851.44
-4,579.52
-3,865.79
-5,907.09
-5,919.1
- -
- -
- -
- -
- -
- -
- -
Working Capital
-1
2
8
12
10
3
-3
4
-5
3
-4
-3
- -
-3
LT Debt
1
1
1
2
6
7
- -
8
- -
- -
3
10
9
10
Total Equity
- -
3
11
19
13
5
4
2
- -
8
-4
-10
-5
-10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-75.46
-60.29
-59.99
-39.47
-40.03
-80.56
-150.11
-259.64
-695.13
-191.24
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
2
5
2
LT Borrowings
2
4
10
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
19
24
46

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
3
3
2
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
8
5
Payables & Accruals
- -
- -
- -
ST Debt
2
5
2
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
351.7%
720.87%
-48.5%
Free Cash Flow
14.81%
37.94%
45.43%
Net Income, GAAP
12.91%
9.75%
25.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.29
2024
- -
- -
-0.13
2025
- -
- -
-0.14

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dominique Jean Francois Marie Doucet
Full Time Employees
22
Sector
Consumer non-durables
Industry
Household/Personal care
Address
38 Avenue de FrEres Montgolfier Lyon AR France 69680
IPO Date
Jul 10, 2015
Website
amoeba-nature.com
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
Amoéba S.A. (ALMIB.PA) develops and markets biological biocides based on Willaertia magna C2c Maky amoeba to control microbial contamination in industry and the environment. The company offers its flagship product Willaertia magna C2c Maky, a naturally occurring predatory amoeba that feeds on pathogenic bacteria such as Legionella pneumophila; liquid biocidal formulations under the brand AMX for applications including water systems, cooling towers, and process waters; and complementary services encompassing on-site testing, implementation support, and customized treatment programs. Amoéba targets industrial sectors vulnerable to biofouling and waterborne pathogens, including cooling systems in power plants, manufacturing facilities, data centers, and hospitals; its primary markets encompass Europe, with expanding operations in North America and Asia. Founded in 2010 and headquartered in Chassieu, near Lyon, France, the company operates as a standalone entity focused on sustainable alternatives to chemical biocides. In recent developments, Amoéba has pursued strategic partnerships, notably collaborating with Veolia on pilot projects for Legionella control in water networks and with Suez for industrial water treatment trials in 2024. The company secured a €3.5 million funding round in late 2024 from existing investors to accelerate AMX commercialization and R&D for agricultural applications. Additionally, Amoéba launched expanded AMX formulations certified for EU biocidal regulations in early 2025 and initiated U.S. market entry via regulatory filings with the EPA. These initiatives reflect a shift toward global scaling and diversified revenue streams beyond initial Legionella-focused sales.